Escient Pharmaceuticals
Acquired
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- escientpharma.com
- Last Round
- Series CNov 2022
About
Escient Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for mast cell-mediated disorders including chronic urticaria, cholestatic pruritus, and atopic dermatitis. Its lead program EP262 targeted MRGPRX2 receptors. Escient was acquired by Incyte Corporation for $750 million in 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account